We’re committed to redefining the autoimmune disease treatment landscape by harnessing the body’s natural killer cells – the immune system’s first responders – to deliver a cell therapy that is safer, more tolerable and more accessible to people living with serious autoimmune diseases, including systemic sclerosis. Watch and learn more:
Nkarta, Inc.
Biotechnology Research
South San Francisco, California 11,569 followers
Harnessing the Power of Natural Killer Cells
About us
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.
- Website
-
http://www.nkartatx.com
External link for Nkarta, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2015
- Specialties
- Cell Therapy and Immuno-Oncology
Locations
-
Primary
Get directions
1150 Veterans Blvd.
South San Francisco, California 94080, US
Employees at Nkarta, Inc.
Updates
-
We’re working to expand the capabilities of #NKcell therapy and address unmet patient needs in autoimmune disease indications such as ANCA Vasculitis. Watch and learn more about how symptoms can manifest.
-
Autoimmune disease represents an area of immense patient need. Hear from David Shook, M.D. on how our passion for patient-centric care translates into our mission to re-define the autoimmune disease treatment landscapes.
-
Hear from our CEO, Paul Hastings, on our vision for the future of NK cell therapy in autoimmune disease, including #lupus.
-
Thank you, Life Science Cares Bay Area for your partnership and for connecting us with non-profits such as BioLink Depot to help the local community.
🌟 Big shoutout to our amazing partners at Nkarta, Inc. 🌟 A massive thank you to the incredible team of 20 volunteers who joined us at BioLink Depot. Together, they made a huge impact by organizing warehouse supplies, fixing broken shelving racks, and creating STEM kits. Thanks to their hard work, teachers will have access to these essential resources for their school year programming. 💪📚🔬 We are so grateful for your dedication and support in helping us empower educators and inspire the next generation of scientists and innovators. Here's to making a difference, one volunteer day at a time! 🙌✨ #CommunityImpact #VolunteerAppreciation #STEMEducation #Nkarta #BiolinkDepot #TogetherWeCan
-
-
Recently, we announced that Columbia University Irving Medical Center initiated an investigator-sponsored trial evaluating NKX019, our allogeneic #NKcell therapy, in people with systemic lupus erythematosus. This broadens the clinical evaluation of NKX019 in #lupus and comes soon after we initiated our lupus nephritis trial last month. Read more here: https://lnkd.in/guhQnueT
-
-
We’re excited to share that Nkarta has been named one of Fortune’s Best Workplaces in the Bay Area for 2024 in the Small/Medium category! This honor is a testament to our incredible team, who helps foster and celebrate our inclusive, people-first environment each day. #GreatPlaceToWork #GPTWcertified
-
-
We're thankful for our partnership with Life Science Cares Bay Area and the important work they do to give back to local organizations.
A huge shoutout to Nkarta, Inc. employees and their family members who volunteered at Florence Fang Community Farm to help with weeding and feeding the chickens. Volunteers are essential to the support and growth of their community farm. Thank you once again, Nkarta! #CommunityEngagement #CorporateResponsibility #NkartaCares #lscbayarea #careactively
-
-
We are pleased to announce the appointment of Nadir Mahmood, Ph.D., to President and the promotion of David Shook, M.D., to Chief Medical Officer, Head of R&D. Learn more about the announcements here: https://lnkd.in/eb6w-ivZ Dr. Mahmood will share executive leadership responsibilities with and report to Paul Hastings, CEO of Nkarta. Dr. Mahmood’s strategic, operational and scientific expertise will be invaluable as we pursue our goal of advancing #NKcell therapies and improving patient outcomes for people living with #autoimmune disease. Dr. Shook, an experienced physician-scientist in the field of cell therapy, will have expanded oversight of the R&D organization, in addition to his existing clinical and regulatory responsibilities. We look forward to seeing him thrive in his new role.
-
-
Today, we announced the initiation of Ntrust-1, a clinical trial of our off-the-shelf natural killer #NKcell therapy candidate, NKX019, in #lupus nephritis. We are also pleased to report that the FDA has cleared our IND application for NKX019, in three additional #autoimmune indications: systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis. We’re steadfast in our mission to develop disruptive cell therapies that are safe and accessible. Read more here: https://lnkd.in/eJ7e-6CY
-